Cerus Corp (CERS) - Multiplikator forward rega marang pendapatan

cerus.com (CERS) - logo korporat

Strategic partnerships with clinics and blood centers are accelerating the expansion of Intercept systems. The forward P/S metric visualizes this process, with the parameter reaching 1.80. A monopoly status in plasma sterilization allows Cerus Corporation (CERS) to exercise pricing power, although high dependence on a single product creates risks associated with the pace of platform implementation in new hospitals.

CERS cerus.com: Multiplikator forward rega marang pendapatan ing interval 04.07.2022 - 16.11.2026

Cerus - rincian analitis lan metrik utama (CERS)

- rega pasar lan target rega analis:
- indikator kapitalisasi pasar:
Analisis umum perusahaan:CERS (Cerus Inc)
Produk asli cerus.com

The market audit of Cerus Corporation (CERS) is based on the valuation of its unique pathogen inactivation systems relative to expected revenue. By analyzing the forward P/S trajectory, an investor determines the premium paid for future sales, which allows for a comparison of current market capitalization against the expansion potential of critical blood safety technologies and confirms the fundamental resilience of the business.

Analisis perusahaan pesaing

Rasio rega marang prakiraan pendapatan Intuitive Surgical Inc ISRG|Multiplikator Forward P/S Danaher Corporation Inc. DHR|BDX - Rasio rega marang prakiraan pendapatan|STERIS plc (STE) - Multiplikator forward rega marang pendapatan|WST: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Baxter International Inc. (BAX)|MASI (masimo.com) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Stevanato Group Corp STVN|Multiplikator forward rega marang pendapatan TFX (Teleflex Inc)|Merit Medical - Kapitalisasi marang prakiraan pendapatan|Envista Holdings - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake ICUI (ICU Medical Inc)|XRAY - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake LeMaitre Corp LMAT|ATRC: Multiplikator Forward P/S|STAA - Rasio kapitalisasi marang dodolan sing dikarepake|NAGE (Chromadex Corp) - Multiplikator Forward P/S|ZimVie Inc (ZIMV) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S ANGO|TKNO: Rega mangsa ngarep marang pendapatan|Rasio rega marang prakiraan pendapatan Monogram Technologies Inc. MGRM|Rega forward marang dodolan STSS|INFU - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan UTMD (Utah Medical Products Inc.)|KORU Medical Systems Inc. (KRMD) - Rasio rega marang prakiraan pendapatan|Nyxoah S.A. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Microbot Medical, Inc.|Kapitalisasi marang prakiraan pendapatan PDEX (Pro-Dex)|Rasio rega marang prakiraan pendapatan Zentek (ZTEK)|Rasio kapitalisasi marang dodolan sing dikarepake Elutia Inc|Multiplikator Forward P/S MLSS (milestonescientific.com)|NXGL: Kapitalisasi marang prakiraan pendapatan|Retractable Tech - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Harvard Bioscience Inc. HBIO|FEMY: Multiplikator Forward P/S|MeihuaMed - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Predictive Oncology Inc|callanjmb.com (CJMB) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Atrion Corporation (ATRI)|Rasio kapitalisasi marang dodolan sing dikarepake neurometrix.com